protein degrader
AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront
AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment
Biohaven’s Phase I Data for Lead Protein Degrader Falls Short of Investor Expectations ###
Biohaven, BHV-1300, Protein degrader, IgG reduction, Phase I study, Investor expectations, Autoimmune disorders, Rheumatoid arthritis, Myasthenia gravis